Yuko Takeba

Dr. Yuko Takeba

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2018 in Cancer Science
Verified
Journal Article
Open access
PDF file
MHMasaki Hara
Masaki Hara
YTYuko Takeba
Yuko Takeba
TITaroh Iiri
Taroh Iiri
YOYuki Ohta
Yuki Ohta
MOMasanori Ootaki
Masanori Ootaki
NMNaoki Matsumoto
Naoki Matsumoto
Vasoactive intestinal peptide (VIP) is a modulator of inflammatory responses. VIP receptors are expressed in several tumor types, such as colorectal carcinoma. The study described herein was conducted to confirm the presence of VIP and its receptors (VPAC1 and VPAC2) in surgically resected hepatocellular carcinoma (HCC) tissues and in the HCC cell line Huh7. The mechanism responsible for apoptosis of HCC cells was then examined because VIP treatment (10−10 M) significantly suppressed proliferation of Huh7 cells. In examining apoptosis‐related proteins, we found caspase‐3 to be significantly increased and Bcl‐xL and cyclic AMP (cAMP) response element‐binding protein (CREB) to be significantly decreased in Huh7 cells cultured with VIP. Furthermore, the CREB level and phosphorylation were reduced. These effects were reversed by the addition of VIP receptor antagonist or cAMP antagonist Rp‐cAMPS. Pretreatment with cAMP analogue blocked the increased apoptosis, suggesting that VIP induces apoptosis via a PKA‐independent signaling mechanism. Our data indicate that VIP prevents the progression of HCC by apoptosis through the cAMP/Bcl‐xL pathway.

20 March 2007 in Life Sciences
Verified
Journal Article
Closed access
TTTadahisa Tomohiro
Tadahisa Tomohiro
TKToshio Kumai
Toshio Kumai
TSTakeo Sato
Takeo Sato
YTYuko Takeba
Yuko Takeba
SKShinichi Kobayashi
Shinichi Kobayashi
KKKenjiro Kimura
Kenjiro Kimura

6 April 2012 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
YTYuko Takeba
Yuko Takeba
NMNaoki Matsumoto
Naoki Matsumoto
MWMinoru Watanabe
Minoru Watanabe
STSachiko Takenoshita-Nakaya
Sachiko Takenoshita-Nakaya
YOYuki Ohta
Yuki Ohta
TOTakehito Otsubo
Takehito Otsubo

Verified
Journal Article
Open access
PDF file
YOYuki Ohta
Yuki Ohta
MTMitsuko Takenaga
Mitsuko Takenaga
AHAkemi Hamaguchi
Akemi Hamaguchi
MOMasanori Ootaki
Masanori Ootaki
YTYuko Takeba
Yuko Takeba
NMNaoki Matsumoto
Naoki Matsumoto
Adipose tissue contains multipotent cells known as adipose-derived stem/stromal cells (ASCs), which have therapeutic potential for various diseases. Although the demand for adipose tissue for research use remains high, no adipose tissue bank exists. In this study, we attempted to isolate ASCs from cryopreserved adipose tissue with the aim of developing a banking system. ASCs were isolated from fresh and cryopreserved adipose tissue of rats and compared for proliferation (doubling time), differentiation capability (adipocytes), and cytokine (hepatocyte growth factor and vascular endothelial growth factor) secretion. Finally, ASCs (2.5 × 106) were intravenously infused into rats with spinal cord injury, after which hindlimb motor function was evaluated. Isolation and culture of ASCs from cryopreserved adipose tissue were possible, and their characteristics were not significantly different from those of fresh tissue. Transplantation of ASCs derived from cryopreserved tissue significantly promoted restoration of hindlimb movement function in injured model rats. These results indicate that cryopreservation of adipose tissue may be an option for clinical application.

1 January 2011 in Journal of Pharmacological Sciences
Verified
Journal Article
Open access
PDF file
YTYuko Takeba
Yuko Takeba
NMNaoki Matsumoto
Naoki Matsumoto
STSachiko Takenoshita-Nakaya
Sachiko Takenoshita-Nakaya
YHYoshie Harimoto
Yoshie Harimoto
TKToshio Kumai
Toshio Kumai
SKShinichi Kobayashi
Shinichi Kobayashi
The aim of this study was to determine suitable culture conditions for maintaining the activity of cytochrome p450 (CYP) 3A4 and drug transporters in primary cultured human hepatocytes. Human hepatocytes were isolated using the two-step collagenase perfusion technique and were cultured with four different media, serum-free William’s E medium (serum-free WEM), WEM containing fetal calf serum (FCS-WEM), WEM with human serum (HS-WEM), and Lanford’s medium. The albumin levels were maintained for 7 days in hepatocytes. Although CYP3A4 mRNA levels gradually decreased from 3 days, CYP3A4 and hepatocyte nuclear factor-4α alpha protein levels and activities were maintained for 7 days in hepatocytes cultured with serum-free WEM and Lanford’s but not in those with FCS-WEM and HS-WEM. Furthermore, CYP3A4 protein levels were significantly increased by the addition of rifampicin and dexamethasone to the culture media, indicating that the induction potential was maintained. The protein levels of P-glycoprotein, multi-drug-resistance-2, and breast cancer-resistance protein were maintained for 7 days in all media. Serum-free WEM and Lanford’s also maintained protein levels of CYP2C19, CYP2D6, and organic anion transporter polypeptide in the hepatocytes. Serum-free WEM and Lanford’s may be appropriate culture media for maintaining CYP3A4 and drug transporter protein levels in primary cultured hepatocytes.

18 April 2019 in JCI Insight
Verified
Journal Article
Open access
PDF file
NMNoriko Makita
Noriko Makita
TATakao Ando
Takao Ando
JSJunichiro Sato
Junichiro Sato
KMKatsunori Manaka
Katsunori Manaka
KMKoji Mitani
Koji Mitani
TITaroh Iiri
Taroh Iiri
Biased agonism is a paradigm that may explain the selective activation of a signaling pathway via a GPCR that activates multiple signals. The autoantibody-induced inactivation of the calcium-sensing receptor (CaSR) causes acquired hypocalciuric hypercalcemia (AHH). Here, we describe an instructive case of AHH in which severe hypercalcemia was accompanied by an increased CaSR antibody titer. These autoantibodies operated as biased allosteric modulators of CaSR by targeting its Venus flytrap domain near the Ca 2+ -binding site. A positive allosteric modulator of CaSR, cinacalcet, which targets its transmembrane domain, overcame this autoantibody effect and successfully corrected the hypercalcemia in this patient. Hence, this is the first study to our knowledge that identifies the interaction site of a disease-causing GPCR autoantibody working as its biased allosteric modulator and demonstrates that cinacalcet can correct the AHH autoantibody effects both in vitro and in our AHH patient. Our observations provide potentially new insights into how biased agonism works and how to design a biased allosteric modulator of a GPCR. Our observations also indicate that the diagnosis of AHH is important because the severity of hypercalcemia may become fatal if the autoantibody titer increases. Calcimimetics may serve as good treatment options for some patients with severe AHH.